Abstrait

A case report of hemophagocytic lymphohistiocytosis (HLH) brought on by EBV reactivation on durvalumab.

Audrey Maury

Background: The condition known as hemophagocytic lymphohistiocytosis poses a major threat to life. So, in order to decrease mortality, it is crucial to understand how to identify it and treat it swiftly.
Methods: In this paper, a case of a 60-year-old female patient with recurrent ovarian cancer is presented. Durvalumab, Bevacizumab, Olaparib, and Durvalumab were all used in her treatment. Her syndrome, which was promptly identified as Hemophagocytic Lymphohistiocytosis (HLH), included fever, dyspnea, anaemia, and thrombocytopenia. The patient's clinical condition was able to normalise thanks to the quick start of the Etoposide, Dexamethasone, and Type G Immunoglobulin treatments.
Results: We propose two potential origins for this syndrome: first, an infectious origin caused by EBV, as well as an immunological origin caused by durvalumab. The patient's clinical condition was able to normalise thanks to the quick start of the Etoposide, Dexamethasone, and Type G Immunoglobulin treatments. To implement a curative treatment as soon as feasible with a reduction in its mortality as our
goal, it is crucial to raise awareness about HLH and its causes.